Vaishali Pharma Ltd

Stage 2 · Advancing · week 7

As of 16 Oct 2026, Vaishali Pharma is in Stage 2 — advancing, the uptrend phase, in week 7 (since 28 Aug 2026). It closed at ₹7.81, 29.6% below its 52-week high and above its 200-day average, which is falling. In Health Care, 40.0% of stocks are in Stage 2.

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. More about the company

₹7.8
+0.26% today
₹102 Cr · Micro cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #57 of 59 in Pharmaceuticals · #68 of 70 in Health Care

Is VAISHALI early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-29.6%
₹4.9 lo₹11.1 hi
29.6% below 52W high — far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 7
1w13w26w
Week 7 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
1.9%
200 DMA: ₹7.7 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.62x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -3.1% vs MA50 +2.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-10.0%
3M
-0.4%
6M
+19.2%
YTD
-16.6%
1Y
-29.6%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #64 of 66 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #54 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 13w
S4 17w
S4 47w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 4w → S1 3w → S4 2w → S1 1w → S4 1w → S1 2w → S4 1w → S1 1w → S4 1w → S1 6w → S2 12w → S3 10w → S2 8w → S3 1w → S4 4w → S1 1w → S2 13w → S3 11w → S4 17w → S1 3w → S4 47w → S1 8w → S4 1w → S1 4w → S2 7w current
Total tracked: 168 weeks across 25 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-28
3 appearances in last 60 days. First seen: 2024-05-16.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 7 · Vol 0.62x
2026-10-15S2
Wk 7 · Vol 0.65x
2026-10-14S2
Wk 7 · Vol 0.52x
2026-10-13S2
Wk 7 · Vol 0.50x
2026-10-12S2
Wk 6 · Vol 0.53x
2026-10-09S2
Wk 6 · Vol 0.54x
2026-10-08S2
Wk 6 · Vol 0.64x
2026-10-07S2
Wk 6 · Vol 1.05x
2026-10-06S2
Wk 6 · Vol 1.34x
2026-10-05S2
Wk 5 · Vol 1.30x
2026-10-01S2
Wk 5 · Vol 1.38x
2026-09-30S2
Wk 5 · Vol 1.24x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹8.3
200 DMA
₹7.7
52W High
₹11.1
52W Low
₹4.9
5D Low
₹7.8
Resistance levels (recent highs)
20d High
₹8.8
60d High
₹9
120d High
₹9
250d High
₹11
Next resistance
+12.5%
to 20d High
Ask the Market AI about VAISHALIAsk →
P/E (TTM)
119.0
Forward —
Earnings Growth (YoY)
+2.0%
Revenue -11.7%
About this companyHealth Care· Pharmaceuticals

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.